Every 10-Q that COGNITION THERAPEUTICS INC (CGTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CGTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CGTX filings page.
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small‑molecule therapies for age‑related CNS disorders. Its lead candidate zervimesine (CT1812) has multiple Phase 2 programs: the NIA‑funded START trial in 545 MCI/early Alzheimer’s patients is fully enrolled, while prior SHINE and SHIMMER studies met safety endpoints and showed biomarker‑linked cognitive and behavioral benefits that are informing planned Phase 3 Alzheimer’s and pivotal DLB psychosis trials in consultation with the FDA and EMA.
For the six months ended June 30, 2026, Cognition reported a net loss of $8,502 (in thousands) versus $15,214 (in thousands) a year earlier, driven by lower research and development expenses of $11,217 (in thousands) compared with $22,267 (in thousands) as large NIA‑funded trials advanced. Grant income declined to $7,497 (in thousands) in line with reduced reimbursable costs. Cash, cash equivalents and restricted cash totaled $34,762 (in thousands) at June 30, 2026, supplemented by approximately $21.6 million of remaining obligated NIA funds and $68.1 million of unused capacity under a 2025 at‑the‑market equity program. Management states these resources are expected to fund operations into the fourth quarter of 2027, assuming no additional ATM usage.
Cognition Therapeutics’ Q1 2026 report shows a smaller loss while it continues advancing its neurology pipeline. Net loss narrowed to $4,570 thousand, or $0.05 per share, compared with $8,480 thousand, or $0.14 per share, a year earlier. Operating expenses fell as research and development dropped to $6,120 thousand from $10,786 thousand, reflecting lower clinical program and personnel costs.
The company generated $3,979 thousand of grant income, mainly from U.S. National Institute on Aging awards funding its Alzheimer’s and dementia with Lewy bodies studies. Cash, cash equivalents and restricted cash totaled $31.2 million, and management believes this, together with existing NIA grant support, can fund operations through the second quarter of 2027. Lead candidate zervimesine (CT1812) remains in multiple Phase 2 programs for Alzheimer’s disease and DLB, with large NIA grants and a 2025 shelf registration and at-the-market program providing additional financing flexibility.
Cognition Therapeutics (CGTX) filed its Q3 2025 10‑Q, highlighting a stronger cash position and continued R&D progress. Cash and cash equivalents were $39.3 million as of September 30, 2025, up from $25.0 million at year‑end 2024, supported by a registered direct offering that raised net proceeds of $27.9 million and ongoing ATM sales. Total assets were $43.4 million and stockholders’ equity was $36.5 million.
The company reported a Q3 net loss of $4.9 million and a nine‑month net loss of $20.1 million, as operating expenses fell year over year. Nine‑month grant income totaled $13.4 million, mitigating R&D spend. Shares outstanding were 88,268,078 as of September 30, 2025, and 88,274,258 as of November 3, 2025. Management states its cash is sufficient to fund operations for the period through one year after this filing, aided by the August financing. Clinical updates included FDA end‑of‑Phase 2 minutes confirming the Phase 3 plan for zervimesine in Alzheimer’s disease and positive Phase 2 signals in dementia with Lewy bodies and geographic atrophy.